📊 Note: Daily ratings and analytics are updated after market close and will be available by 7:00 PM IST.

Details

NameSymbolSector
EIKO LIFESCIENCES LIMITEDEIKOSpecialty Chemicals
Open
49.8
High
50.8
Low
48.99
Close
49.48
Volume
25635
Exchange
bse
Time
21-May-2026

Outlook

Score:  

0.75

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Eiko Lifesciences is  
Short Body
Estimated Stoploss of Eiko Lifesciences is ₹  
50.8
Eiko Lifesciences has a  
Bearishℹ
 pattern. 
Formation of  
Short Body
 candle pattern indicates the trend direction of Eiko Lifesciences is  
Unpredictableℹ
. 

Trend

Eiko Lifesciences is in  
Sideways trendℹ
. 
Price of Eiko Lifesciences is  
Downℹ
 by  

2.43

%. 
Target
Buy @ 

48.14

Sell @ 

54.28

Current @ 

49.48

Volume

The trades of Eiko Lifesciences have been in  
Immenseℹ
 volume. 
The volume trades for Eiko Lifesciences are  
Bearishℹ
 with  
Strong Sellersℹ
The trade volume of Eiko Lifesciences is  

Up

 by  

186.65

% 

Valuation

The current market price of Eiko Lifesciences is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 66cr and total assets worth ₹ 66cr, the balance sheet of Eiko Lifesciences is:  
Balancedℹ
. 
Cashflow
Eiko Lifesciences has  
Insufficientℹ
 cash flow because there is  

Shortage

 of  

₹ 1cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

10.53% i.e. ₹ 2cr earned in operatingℹ
57.89% i.e. ₹ 11cr spent in investingℹ
31.58% i.e. ₹ 6cr earned in financingℹ
0% in otherℹ
Income
The income of Eiko Lifesciences is  

₹ 11cr

 and  

Profit

 is :  

₹ 1cr

(*Sep 2025)

Eiko Lifesciences Profit is up by:  

0

% and Income is Up by:  

10

% 

(*Sep 2025)

The income of Eiko Lifesciences is  

₹ 10cr

 and  

Profit

 is :  

₹ 1cr

(*Jun 2025)

Eiko Lifesciences Profit is up by:  

0

% and Income is Down by:  

9.09

% 

(*Jun 2025)

The income of Eiko Lifesciences is  

₹ 11cr

 and  

Profit

 is :  

₹ 1cr

(*Mar 2025)

Eiko Lifesciences Profit is up by:  

100

% and Income is Up by:  

57.14

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.